

# AGI-6780

Catalog No: tcsc1556



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

1432660-47-3

**Formula:**

$C_{21}H_{18}F_3N_3O_3S_2$

**Pathway:**

Metabolic Enzyme/Protease

**Target:**

Isocitrate Dehydrogenase (IDH)

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 29$  mg/mL (60.23 mM)

**Observed Molecular Weight:**

481.51


## Product Description

AGI-6780 that potently and selectively inhibits the tumor-associated mutant **IDH2<sup>R140Q</sup>** with **IC<sub>50</sub>** of 23±1.7 nM. AGI-6780 is less

potent against **IDH2<sup>WT</sup>** with **IC<sub>50</sub>** of 190±8.1 nM.

IC50 & Target: IC50: 23±1.7 nM (IDH2<sup>R140Q</sup>), 190±8.1 nM (IDH2<sup>WT</sup>)<sup>[1]</sup>

***In Vitro:*** AGI-6780 is tested in both human glioblastoma U87 and TF-1 cells expressing IDH2<sup>R140Q</sup>, as well as against IDH1<sup>R132H</sup> for 48 h incubation, with IC50 of 11±2.6 nM, 18±0.51 nM, and >1 mM, respectively. Treatment of TF-1<sup>R140Q</sup> cells with AGI-6780, at concentrations that lower 2HG to near-normal physiologic levels, restore expression of both HBG and KLF1 genes and the color change associated with differentiation. AGI-6780 can reverse the IDH2<sup>R140Q</sup>-induced differentiation block in TF-1 cells. Pretreatment with AGI-6780 (0.2 µM and 1 µM) markedly decreased the intracellular concentration of (R)-2-hydroxyglutarate in the TF1<sup>R140Q</sup> cells and restored their ability to undergo EPO-induced differentiation<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!